Literature DB >> 21119165

A critique of revision rate as an outcome measure: re-interpretation of knee joint registry data.

J W Goodfellow1, J J O'Connor, D W Murray.   

Abstract

National registers compare implants by their revision rates, but the validity of the method has never been assessed. The New Zealand Joint Registry publishes clinical outcomes (Oxford knee scores, OKS) alongside revision rates, allowing comparison of the two measurements. In the two types of knee replacement, unicompartmental (UKR) had a better knee score than total replacement (TKR), but the revision rate of the former was nearly three times higher than that of the latter. This was because the sensitivity of the revision rate to clinical failure was different for the two implants. For example, of knees with a very poor outcome (OKS < 20 points), only about 12% of TKRs were revised compared with about 63% of UKRs with similar scores. Revision therefore is not an objective measurement and should not be used to compare these two types of implant. Furthermore, revision is much less sensitive than the OKS to clinical failure in both types and therefore exaggerates the success of knee replacements, particularly of TKR.

Entities:  

Mesh:

Year:  2010        PMID: 21119165     DOI: 10.1302/0301-620X.92B12.25193

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  44 in total

1.  Early migration of the cemented tibial component of unicompartmental knee arthroplasty: a radiostereometry study.

Authors:  Andrea Ensini; Paolo Barbadoro; Alberto Leardini; Fabio Catani; Sandro Giannini
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-06-04       Impact factor: 4.342

2.  Using financial incentives to improve value in orthopaedics.

Authors:  David Lansky; Benedict U Nwachukwu; Kevin J Bozic
Journal:  Clin Orthop Relat Res       Date:  2012-04       Impact factor: 4.176

3.  The Oxford unicompartmental knee fails at a high rate in a high-volume knee practice.

Authors:  William C Schroer; C Lowry Barnes; Paul Diesfeld; Angela LeMarr; Rachel Ingrassia; Diane J Morton; Mary Reedy
Journal:  Clin Orthop Relat Res       Date:  2013-08-02       Impact factor: 4.176

Review 4.  Causes of revision following Oxford phase 3 unicompartmental knee arthroplasty.

Authors:  Seung-Ju Kim; Ricardo Postigo; Sowon Koo; Jong Hun Kim
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-09-01       Impact factor: 4.342

5.  CORR Insights ®: The Oxford unicompartmental knee fails at a high rate in a high-volume knee practice.

Authors:  John M Clark
Journal:  Clin Orthop Relat Res       Date:  2013-08-24       Impact factor: 4.176

Review 6.  Larger range of motion and increased return to activity, but higher revision rates following unicompartmental versus total knee arthroplasty in patients under 65: a systematic review.

Authors:  Laura J Kleeblad; Jelle P van der List; Hendrik A Zuiderbaan; Andrew D Pearle
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-11-28       Impact factor: 4.342

Review 7.  [Focal femoral resurfacing and unicompartmental knee replacement : Between osteotomy and total knee replacement].

Authors:  Philipp Henle; Matthias J Feucht; Christian Stärke
Journal:  Orthopade       Date:  2021-04-13       Impact factor: 1.087

Review 8.  Hip resurfacing: a systematic review of literature.

Authors:  Régis Pailhé; Akash Sharma; Nicolas Reina; Etienne Cavaignac; Philippe Chiron; Jean-Michel Laffosse
Journal:  Int Orthop       Date:  2012-10-26       Impact factor: 3.075

9.  When do patient-reported assessments peak after revision knee arthroplasty?

Authors:  Ajay Malviya; Karen Bettinson; Steven M Kurtz; David J Deehan
Journal:  Clin Orthop Relat Res       Date:  2011-11-05       Impact factor: 4.176

10.  Results of a French multicentre retrospective experience with four hundred and eighteen failed unicondylar knee arthroplasties.

Authors:  Dominique Saragaglia; Michel Bonnin; David Dejour; Gérard Deschamps; Christophe Chol; Benoit Chabert; Ramsay Refaie
Journal:  Int Orthop       Date:  2013-05-29       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.